{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '13.', 'APPENDICES', 'Amendment 2: 06 March 2019', '144', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '13.1 Appendix 1: Methotrexate Dose Reduction Guidelines', 'ALT and/or AST', 'Total Bilirubin', 'Repeat Laboratory', 'MTX', 'Study Treatment', '1x to <2x ULN', 'NA', 'No need', 'No change', 'No change', '>2x to <3x ULN', 'NA', 'Within 1 week', 'No change or can consider reduction', 'in dose', 'No change', 'If repeat >2x to <3x ULN', 'NA', 'Within 1 week', 'Reduce dosage and follow LFTs', 'No change', '>3x to <8x ULN', 'Within 72 hours of initial finding,', '(without the appearance of', 'and then at least weekly after last', 'Hold MTX until LFTs normalize or', 'fatigue, nausea, vomiting, right', 'finding until resolution,', '<2x ULN', 'return to baseline and consider', 'upper quadrant pain or', 'stabilization, or return to baseline', 'No change', 'tenderness, fever, rash, and/or', 'values', 'restarting at lower dose', 'eosinophilia [>5%])', 'If repeat >3x to <8x ULN', 'Within 72 hours of initial finding,', '(without the appearance of', 'and then at least weekly after last', 'Hold and consider', 'Hold MTX until LFTs normalize or', 'fatigue, nausea, vomiting, right', 'finding until resolution,', 'restarting after discussion', '<2x ULN', 'return to baseline and consider', 'with the R-Pharm', 'upper quadrant pain or', 'stabilization, or return to baseline', 'restarting at lower dose', 'International Medical', 'tenderness, fever, rash, and/or', 'values', 'Advisor or designee', 'eosinophilia [>5%])', '>3x ULN accompanied by', 'Within 72 hours of initial finding,', 'symptoms which, as determined', 'and then at least weekly after last', 'by the Investigator, are the result', 'finding until resolution,', 'Hold MTX. Follow local Standard', 'X ULN', 'Permanently discontinue', 'of hepatic injury (e.g., fatigue,', 'stabilization, or return to baseline', 'of Care.', 'study treatment', 'nausea, vomiting, right upper', 'values', 'quadrant pain or tenderness,', 'fever, rash, eosinophilia (>5%)', 'Within 72 hours of initial finding,', 'and then at least weekly after last', 'Hold MTX. Follow local Standard', '>3x ULN', 'Permanently discontinue', '>2x ULN', 'finding until resolution,', 'of Care.', 'study treatment', 'stabilization, or return to baseline', 'values', 'Amendment 2: 06 March 2019', '145', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'ALT and/or AST', 'Total Bilirubin', 'Repeat Laboratory', 'MTX', 'Study Treatment', 'Within 72 hours of initial finding,', '>5x ULN for for', 'and then at least weekly after last', 'Hold MTX. Follow local Standard', 'Permanently discontinue', '<2x ULN', 'finding until resolution,', '>2 consecutive weeks', 'of Care.', 'stabilization, or return to baseline', 'study treatment', 'values', 'Within 72 hours of initial finding,', 'and then at least weekly after last', 'Hold MTX. Follow local Standard', '>8x ULN', 'Permanently discontinue', '<2x ULN', 'finding until resolution,', 'of Care.', 'stabilization, or return to baseline', 'study treatment', 'values', 'Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; MTX = methotrexate; LFTs = liver function tests; NA = not applicable; ULN = upper', 'limit', 'of', 'normal.', 'Amendment 2: 06 March 2019', '146', 'Confidential']\n\n###\n\n", "completion": "END"}